Immune responses in cancer

被引:119
作者
Adam, JK
Odhav, B
Bhoola, KD
机构
[1] Univ Western Australia, Sir Charles Gairdiner Hosp, Asthma & Allergy Res Inst, Nedlands, WA 6009, Australia
[2] Durban Inst Technol, Dept Biol Sci, Durban, South Africa
[3] Durban Inst Technol, Dept Med Sci, Durban, South Africa
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
carcinogenesis; immunity; immunotherapy; tumour antigens and surveillance; vaccines;
D O I
10.1016/S0163-7258(03)00056-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The complex of Immoral factors and immune cells comprises two interleaved systems, innate and acquired. Immune cells scan the occurrence of any molecule that it considers to be nonself. Transformed cells acquire antigenicity that is recognized as nonself. A specific immune response is generated that results in the proliferation of antigen-specific lymphocytes. Immunity is acquired when antibodies and T-cell receptors are expressed and up-regulated through the formation and release of lymphokines, chemokines, and cytokines. Both innate and acquired immune systems interact to initiate antigenic responses against carcinomas. A new approach to the treatment of cancer has been immunotherapy, which aims to up-regulate the immune system in order that it may better control carcinogenesis. Currently, several forms of immunotherapy that use natural biological substances to activate the immune system are being explored therapeutically. The various forms of immunotherapy fall into three main categories: monoclonal antibodies, immune response modifiers, and vaccines. While these modalities have individually shown some promise, it is likely that the best strategy to combat cancer may require multiple immunotherapeutic strategies in order to demonstrate benefit in different patient populations. It may be that the best results are obtained with vaccines in combination with a variety of immunotherapy combinations. Another potent strategy may be in combining with more traditional cancer drugs as evidenced from the benefit derived from enhancing the efficacy of chemotherapy with cytokines. Through such concerted efforts, a durable, therapeutic antitumour immune response may be achieved and maintained over the course of a patient's lifespan. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:113 / 132
页数:20
相关论文
共 123 条
  • [1] Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma
    Adler, HL
    McCurdy, MA
    Kattan, MW
    Timme, TL
    Scardino, PT
    Thompson, TC
    [J]. JOURNAL OF UROLOGY, 1999, 161 (01) : 182 - 187
  • [2] UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE
    ALLAN, NC
    RICHARDS, SM
    SHEPHERD, PCA
    [J]. LANCET, 1995, 345 (8962) : 1392 - 1397
  • [3] CYTOKINES AND CYTOKINE INHIBITORS OR ANTAGONISTS IN RHEUMATOID-ARTHRITIS
    AREND, WP
    DAYER, JM
    [J]. ARTHRITIS AND RHEUMATISM, 1990, 33 (03): : 305 - 315
  • [4] INTERLEUKIN-1 RECEPTOR ANTAGONIST
    AREND, WP
    [J]. ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 : 167 - 227
  • [5] Atkins MB, 1997, CLIN CANCER RES, V3, P409
  • [6] ATTARDI LD, 1993, CELL, V74, P597
  • [7] Thirteen-year, long-term efficacy of interferon 2α and interleukin 2-based home therapy in patients with advanced renal cell carcinoma
    Atzpodien, J
    Hoffmann, R
    Franzke, M
    Stief, C
    Wandert, T
    Reitz, M
    [J]. CANCER, 2002, 95 (05) : 1045 - 1050
  • [8] BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
  • [9] NEUTROPHIL-ACTIVATING PEPTIDE-1 INTERLEUKIN-8, A NOVEL CYTOKINE THAT ACTIVATES NEUTROPHILS
    BAGGIOLINI, M
    WALZ, A
    KUNKEL, SL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) : 1045 - 1049
  • [10] Response of hairy cells to IFN-α involves induction of apoptosis through autocrine TNF-α and protection by adhesion
    Baker, PK
    Pettitt, AR
    Slupsky, JR
    Chen, HJ
    Glenn, MA
    Zuzel, M
    Cawley, JC
    [J]. BLOOD, 2002, 100 (02) : 647 - 653